Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Upgrading business potential of Enzybiotx

Project description

Deep-tech discovery platform for tailor-made enzybiotics

Overuse of antibiotics, particularly in agriculture, has led to the emergence of antibiotic resistance. Furthermore, lack of investment in the discovery of new antibiotics has meant bacterial infections are on the rise due to a lack of effective remedies. Enzybiotics, bacteriolytic enzymes that in a very effective and selective way eliminate bacteria, including antibiotic-resistant strains, and display very low resistance prevalence, is one of a number of promising new approaches. The EU-funded ENZYBIOTX project provides a deep-tech discovery platform for tailor made-enzybiotics, targeting specific pathogenic bacteria to address the need for alternative development of antimicrobials. The proprietary technology allows the company to collaborate with clients to create specific enzymes and perform all the tests needed to adjust their properties before introducing them into a final product.

Objective

Since the discovery of penicillin people were living in justified confidence that available antibiotics can cure any bacterial infections. Emerging antibiotic resistance was usually overcome by treatment with new generation of antibiotics, but during last decades bacteria are clearly winning this race. Overuse of antibiotics, particularly in agriculture, and lack of investments in discovery of new antibiotics lead us to situation when increasing number of bacterial infections cannot be cured due to lack of effective remedy. Antibiotic resistance surveillance revealed rising antibiotic resistance around the world. WHO predicts that if no appropriate actions are taken by 2050 antibiotic resistance will be responsible even for 10 mln deaths every year. To address this urgent medical need new antibiotics and alternative methods of combating antibiotic resistant bacteria are needed. One of the new approaches which is getting more and more interests among academic and industrial research groups are enzybiotics, bacteriolytic enzymes that in a very effective and selective way eliminate bacteria, including antibiotic resistant strains, at the same time displaying very low resistance prevalence. Enzybiotx provides a deep-tech platform for tailor made-enzybiotics targeting specific bacteria. Our company has developed the platform for design and generation of new enzybiotcs to target pathogenic bacteria of interest as an answer to the need of alternative antimicrobials development. The company in collaboration with potential clients is able to prepare tailor-made enzybiotics which target pathogens and in collaboration with the client, perform all tests needed to adjust enzyme’s properties to be able to introduce them to the final products.
The founders of the company are experienced academics who have gathered unique expertise in isolation and characterisation of new enzybiotics.

Coordinator

ENZYBIOTX SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Net EU contribution
€ 75 000,00
Address
AL. ZWYCIESTWA 241/13
81-521 GDYNIA
Poland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Makroregion północny Pomorskie Trójmiejski
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data